Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021198929 - ANTI-IL6 AGENT FOR TREATING CORONAVIRUS INFECTION

Publication Number WO/2021/198929
Publication Date 07.10.2021
International Application No. PCT/IB2021/052659
International Filing Date 30.03.2021
IPC
A61K 39/42 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
CPC
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
C07K 16/248
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
244Interleukins [IL]
248IL-6
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applicants
  • JANSSEN BIOTECH, INC. [US]/[US]
Inventors
  • BOVEN, Katia
  • CHIEN, Jason
  • OPSOMER, Magda
  • WOODFALL, Brian
Agents
  • SHIRTZ, Joseph F.
  • DICHTER, Eric A.
Priority Data
63/002,88031.03.2020US
63/012,75820.04.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-IL6 AGENT FOR TREATING CORONAVIRUS INFECTION
(FR) AGENT ANTI-IL6 POUR LE TRAITEMENT D'INFECTION À CORONAVIRUS
Abstract
(EN) An anti-IL6 agent that blocks binding of IL-6 to IL-6 receptor, for example, an anti-IL6 antibody comprising a heavy chain variable region of SEQ ID NO:99 and a light chain variable region of SEQ ID NO:97, is useful in the treatment or prevention of infection of a human with SARS-CoV-1 and/or SARS-CoV-2.
(FR) L'invention concerne un agent anti-IL6 qui bloque la liaison d'IL-6 à un récepteur d'IL-6, par exemple, un anticorps anti-IL6 comprenant une région variable de chaîne lourde de SEQ ID NO:99 et une région variable de chaîne légère de SEQ ID NO:97, est utile dans le traitement ou la prévention d'une infection d'un être humain par le SARS-CoV-1 et/ou le SARS-CoV-2.
Latest bibliographic data on file with the International Bureau